Moisand Fitzgerald Tamayo’s ResMed RMD Stock Holding History

Moisand Fitzgerald Tamayo’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22	Closed	-$4.81K	–	814
2023 Q2	$4.81K	Hold	22	–	–	﹤0.01%	423
2023 Q1	$4.82K	Hold	22	–	–	﹤0.01%	426
2022 Q4	$4.58K	Buy	22 +17	+340%	+$3.73K	﹤0.01%	422
2022 Q3	$1K	Sell	5 -7	-58%	-$1.59K	﹤0.01%	647
2022 Q2	$3K	Sell	12 -11	-48%	-$2.34K	﹤0.01%	378
2022 Q1	$6K	Buy	+23	New	+$5.56K	﹤0.01%	244

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Moisand Fitzgerald Tamayo's RMD Position: Q3 2023 in Review

Moisand Fitzgerald Tamayo sold out of ResMed (RMD) in Q3 2023, closing a stake of 22 shares — an estimated $4.81K sold.

Moisand Fitzgerald Tamayo first reported a position in RMD in Q1 2022 and held it in 6 quarters. The position peaked at $6K in Q1 2022. 657 funds tracked by Wall St. Rank hold RMD as of Q3 2023.

Moisand Fitzgerald Tamayo reported no remaining ResMed position as of Q3 2023 after selling out during the quarter.
Moisand Fitzgerald Tamayo sold 22 ResMed shares in Q3 2023, an estimated $4.81K.
Moisand Fitzgerald Tamayo first reported a position in ResMed in Q1 2022 and held it in 6 quarters.
Moisand Fitzgerald Tamayo's ResMed position peaked at $6K in Q1 2022.
657 funds tracked by Wall St. Rank held ResMed as of Q3 2023.

Based on Moisand Fitzgerald Tamayo's 13F filing for Q3 2023, filed 20 Oct 2023.